Jubilant Pharmova (530019) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
16 Nov, 2026Executive summary
Q1'FY27 revenue was ₹22,211 million (Rs. 2,229 Cr.), up 17% YoY; EBITDA was Rs. 268 Cr., down 11%, and consolidated profit was ₹564 million, down 45%.
Growth was led by CDMO sterile injectables and Radiopharma; lower SPECT availability and Montreal remediation costs weighed on profitability.
Vision 2030 targets revenue at 2x FY24 levels, 23%–25% EBITDA margin, zero net debt and high-teens ROCE.
Financial highlights
Revenue from operations was ₹22,211 million, versus ₹18,789 million in Q1 FY26 and ₹22,722 million in Q4 FY26; total income was Rs. 2,249 Cr., up 18% YoY.
Consolidated profit was ₹564 million, versus ₹1,025 million in Q1 FY26 and ₹1,193 million in Q4 FY26; basic EPS was ₹3.57, versus ₹6.49 and ₹7.55, respectively.
Standalone revenue was ₹671 million, versus ₹595 million in Q1 FY26 and ₹703 million in Q4 FY26; standalone profit was ₹74 million, versus ₹57 million and ₹571 million, respectively.
EBITDA was Rs. 268 Cr., down 11% YoY; margin contracted 385 bps to 11.9%. Reported and normalized PAT were Rs. 56 Cr., down 45%, with reported PAT margin at 2.5%.
Unaudited standalone and consolidated results for the quarter ended June 30, 2026, were approved by the Board and prepared under Ind AS and SEBI regulations.
Outlook and guidance
Vision 2030 targets revenue of Rs. 13,500 Cr. and EBITDA margin of 23%–25%, versus TTM revenue of Rs. 8,608 Cr. and margin of 15%.
Radiopharma targets revenue above 2x FY24 by FY30; margins are expected to improve after H2'FY27 as Montreal supply normalizes, with new products launching from FY28.
Six PET sites are planned to expand the network from 3 to 9, with full operation by FY28; existing-site expansion is also expected to support growth.
CDMO sterile injectables targets more than 2x FY24 revenue and margin above 25% by FY30; Line 3 and Line 4 are scaling, with Montreal Line 5 technology-transfer revenue expected from FY29.
Drug Discovery Services targets ~3x FY24 revenue by FY30; Generics targets ~2x FY24 revenue and 15%–17% margin, while API targets 2x FY24 revenue and margin above 15%.
Latest events from Jubilant Pharmova
- Revenue rose 21%, while lower SPECT supply and costs cut EBITDA 27%.530019
Q2 26/27 - Record FY20 profitability came with COVID-19 disruption and deferred capex.530019
Q4 19/20 - Pharmaceuticals drove record revenue, while the IFC settlement weighed on reported profit.530019
Q4 18/19 - Products growth offset weaker Services as FY11 results absorbed demerger and H1N1 comparisons.530019
Q4 10/11 - Record FY17 results, injectables momentum and lower leverage offset significant operating risks.530019
Q4 16/17 - EBITDA climbed 76% as pharma growth drove a strong FY16 earnings recovery.530019
Q4 15/16 - Record FY18 growth, led by specialty pharma and ingredients, alongside debt reduction and Triad integration.530019
Q4 17/18 - Flat revenue masked weaker earnings; radiopharma growth and FY16 recovery plans offered offsets.530019
Q4 14/15 - Revenue grew 12%, while exceptional costs and sterile-compliance issues weighed on profit.530019
Q4 13/14